Bicycle Therapeutics (BCYC) News Today $13.39 +0.62 (+4.86%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$13.40 +0.00 (+0.04%) As of 01/31/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Bicycle Therapeutics plc (NASDAQ:BCYC) Sees Significant Growth in Short InterestBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 14.9% from the December 31st total of 3,430,000 shares. Based on an average daily volume of 591,800 shares, the days-to-cover ratio is presently 6.7 days.February 1 at 7:16 AM | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase - Here's What HappenedJanuary 31 at 1:34 PM | marketbeat.comBicycle Health reached profitability as it raised $16.5 million to scale virtual opioid use disorder treatment to more patients nationallyJanuary 30 at 1:51 PM | finance.yahoo.comStephens Reaffirms Equal Weight Rating for Bicycle Therapeutics (NASDAQ:BCYC)January 24, 2025 | americanbankingnews.comCantor Fitzgerald Predicts BCYC FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for BCYC FY2025 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Bicycle Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.24) peJanuary 23, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Trading Down 5.2% - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Trading Down 5.2% - Here's WhyJanuary 22, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) Equal Weight Rating Reaffirmed at StephensStephens reiterated an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday.January 22, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Down 3.9% - Time to Sell?Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 3.9% - Should You Sell?January 16, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for BCYC EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Bicycle Therapeutics in a research note issued on Monday, January 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will postJanuary 16, 2025 | marketbeat.comOptimistic Outlook on Bicycle Therapeutics Amid Mixed Clinical Results and Strategic RoadmapJanuary 15, 2025 | markets.businessinsider.comBicycle Therapeutics: Promising Cancer Therapy Developments and Growth Opportunities Support Buy RatingJanuary 14, 2025 | markets.businessinsider.comForecasting The Future: 11 Analyst Projections For Bicycle TherapeuticsJanuary 14, 2025 | benzinga.comBicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and MilestonesJanuary 13, 2025 | stockhouse.comBicycle Therapeutics Announces Topline Phase 1 Data For Zelenectide Pevedotin Plus PembrolizumabJanuary 13, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's What HappenedJanuary 13, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Monday.January 13, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Bicycle Therapeutics (NASDAQ:BCYC)Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday.January 13, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of "Moderate Buy" from AnalystsBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to tJanuary 10, 2025 | marketbeat.comBicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | businesswire.comAlethia Young Sells 1,395 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockJanuary 7, 2025 | insidertrades.comAlethia Young Sells 1,395 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CFO Alethia Young sold 1,395 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $19,655.55. Following the completion of the sale, the chief financial officer now owns 45,605 shares of the company's stock, valued at $642,574.45. This trade represents a 2.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.January 6, 2025 | marketbeat.comInsider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells 1,750 Shares of StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CAO Travis Alvin Thompson sold 1,750 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $24,657.50. Following the transaction, the chief accounting officer now owns 34,991 shares of the company's stock, valued at approximately $493,023.19. This represents a 4.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 6, 2025 | marketbeat.comTravis Alvin Thompson Sells 2,686 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CAO Travis Alvin Thompson sold 2,686 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares of the company's stock, valued at $482,190. This represents a 7.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.January 6, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner Sells 3,287 SharesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CTO Michael Skynner sold 3,287 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $46,313.83. Following the completion of the sale, the chief technology officer now directly owns 124,658 shares in the company, valued at approximately $1,756,431.22. The trade was a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.January 6, 2025 | marketbeat.comInsider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells 4,578 Shares of StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) COO Alistair Milnes sold 4,578 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now owns 100,724 shares in the company, valued at $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 6, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Insider Sells $69,646.87 in StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) insider Santiago Arroyo sold 4,943 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the transaction, the insider now owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.January 6, 2025 | marketbeat.comKevin Lee Sells 9,038 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 9,038 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now owns 495,026 shares in the company, valued at $6,974,916.34. The trade was a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.January 6, 2025 | marketbeat.comBicycle Therapeutics PLC ADRJanuary 4, 2025 | morningstar.comBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | businesswire.comState Street Corp Grows Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)State Street Corp raised its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 233.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 86,271 shares of the company's stock after buying an additional 60,399 shares during the peJanuary 2, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 4.5% - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Shares Down 4.5% - Here's WhyDecember 31, 2024 | marketbeat.comPrincipal Financial Group Inc. Makes New $10.03 Million Investment in Bicycle Therapeutics plc (NASDAQ:BCYC)Principal Financial Group Inc. acquired a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 443,141 shares of the company's stock, valued at approximately $December 31, 2024 | marketbeat.comBicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strengthDecember 20, 2024 | investing.comBicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.9% Following Analyst DowngradeBicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.9% After Analyst DowngradeDecember 19, 2024 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for BCYCBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, December 16th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.December 19, 2024 | marketbeat.comBicycle Therapeutics price target lowered to $26 from $32 at JMP SecuritiesDecember 18, 2024 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up on Insider Buying ActivityBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up on Insider Buying ActivityDecember 18, 2024 | marketbeat.comJMP Securities Has Lowered Expectations for Bicycle Therapeutics (NASDAQ:BCYC) Stock PriceJMP Securities decreased their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a report on Wednesday.December 18, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $7,670,000.00 in StockDecember 18, 2024 | insidertrades.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $7,670,000.00 in StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker acquired 500,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was purchased at an average price of $15.34 per share, for a total transaction of $7,670,000.00. Following the purchase, the director now owns 9,995,274 shares of the company's stock, valued at $153,327,503.16. The trade was a 5.27 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.December 17, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $13,559,062.72 in StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker purchased 985,397 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares of the company's stock, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 17, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Sees Unusually-High Trading Volume - What's Next?Bicycle Therapeutics (NASDAQ:BCYC) Sees Strong Trading Volume - Should You Buy?December 17, 2024 | marketbeat.comBreaking Down Bicycle Therapeutics: 8 Analysts Share Their ViewsDecember 16, 2024 | benzinga.comBicycle Therapeutics (NASDAQ:BCYC) Shares Up 8.7% - Should You Buy?Bicycle Therapeutics (NASDAQ:BCYC) Trading 8.7% Higher - Here's WhyDecember 16, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $33.00 by Analysts at HC WainwrightHC Wainwright cut their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating for the company in a research note on Monday.December 16, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of "Moderate Buy" by BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has received an average rating of "Moderate Buy" from the nine brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company.December 16, 2024 | marketbeat.comBicycle Therapeutics plc (BCYC)December 14, 2024 | finance.yahoo.comFmr LLC Purchases New Shares in Bicycle Therapeutics plc (NASDAQ:BCYC)Fmr LLC purchased a new stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 150,516 shares of the company's stock, valued at approximately $3,406,000. Fmr LLC owned approximately 0.32%December 14, 2024 | marketbeat.comWe're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash WiselyDecember 13, 2024 | finance.yahoo.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.440.69▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼55▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTC Therapeutics News Today Crinetics Pharmaceuticals News Today Rhythm Pharmaceuticals News Today Akero Therapeutics News Today Arcellx News Today Immunovant News Today Denali Therapeutics News Today ACADIA Pharmaceuticals News Today Xenon Pharmaceuticals News Today Twist Bioscience News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts